[Etoricoxib (Arcoxia)].

Abstract

Etoricoxib (Arcoxia) is a novel non steroidal anti-inflammatory drug (NSAID) that selectively inhibits the inducible form of cyclo-oxygenase (COX), COX-2. Etoricoxib has a higher COX-1/COX-2 selectivity ratio than the other COX-2-selective NSAIDs as rofecoxib, valdecoxib or celecoxib. Tablets of 60, 90 and 120 mg are available. The recommended dosage of etoricoxib is 60 mg/day for osteoarthritis, 90 mg/day for rheumatoid arthritis and 120 mg/day for acute gouty arthritis. Etoricoxib's efficacy has been widely studied in comparative studies, showing the same efficacy as non-COX-2 selective NSAID, with fewer gastro-intestinal adverse effects.

• Authors: P Leclercq, M G Malaise
• Journal: Revue medicale de Liege (Rev Med Liege) Vol. 59 Issue 5 Pg. 345-9 (May 2004) ISSN: 0370-629X [Print] Belgium
• Vernacular Title: Le médicament du mois. Etoricoxib (Arcoxia).
• PMID: 15270001 (Publication Type: Journal Article, Review)

Chemical References

• Anti-Inflammatory Agents, Non-Steroidal
• Isoenzymes
• Membrane Proteins
• Pyridines
• Sulfones
• Cyclooxygenase 2
• PTGS2 protein, human
• Prostaglandin-Endoperoxide Synthases
• Etoricoxib

Topics

• Administration, Oral
• Anti-Inflammatory Agents, Non-Steroidal (administration & dosage, adverse effects, therapeutic use)
• Arthritis, Gouty (drug therapy)
• Arthritis, Rheumatoid (drug therapy)
• Cyclooxygenase 2
• Etoricoxib
• Humans
• Isoenzymes (antagonists & inhibitors)
• Membrane Proteins
• Osteoarthritis (drug therapy)
• Prostaglandin-Endoperoxide Synthases
• Pyridines (administration & dosage, adverse effects, therapeutic use)
• Sulfones (administration & dosage, adverse effects, therapeutic use)